Risk factors for anthracycline-associated cardiotoxicity
Raquel E. Reinbolt(The Ohio State University), Maryam B. Lustberg(Yale Cancer Center), Roshan M. Patel(The Ohio State University), Xueliang Pan(The Ohio State University), Charles L. Shapiro(Tisch Hospital), Robert Pilarski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Cynthia Timmers(Cancer Genetics (United States))
Cited by 48
Related Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
|Journal of the National Comprehensive Cancer Network|2016|660
Genetic/Familial High-Risk Assessment: Breast and Ovarian
|Journal of the National Comprehensive Cancer Network|2010|650
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|507